RGBPP
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 0.01 | $59,065 | -$63,234 |
| 2025 Q1 | -0.01 | $59,065 | -$197,941 |
| 2025 Q4 | -0.01 | $59,366 | -$160,005 |
| 2025 Q3 | -0.01 | $59,065 | -$55,977 |
| 2025 Q2 | -0.00 | $59,065 | -$101,230 |
| 2024 Q1 | -0.07 | $59,065 | -$66,380 |
| 2024 Q4 | -0.06 | $59,366 | -$148,900 |
| 2024 Q3 | -0.03 | $59,065 | -$172,590 |